文献速递免疫规划慢病防控与筛查

丹麦带状疱疹疫苗接种前流行病学:发病情况与危险因素的量化

Prevaccination epidemiology of herpes zoster in Denmark: Quantification of occurrence and risk factors.
PubMed 文献 · Vaccine · 2017-09-02

研究基于丹麦全国登记数据构建并验证带状疱疹识别算法,纳入1997-2013年≥40岁首次使用阿昔洛韦、伐昔洛韦或泛昔洛韦处方或住院诊断者。验证子研究(n=176)显示87%(95%CI 79-93%)确认为带状疱疹;队列研究(45,297,258人年)显示发病率随年龄上升,女性最高,3.5%在住院期间诊断;病例对照研究(n=189,025例 vs 945,111对照)显示严重免疫抑制者OR最高(1.82-4.12),多种自身免疫病、哮喘、慢性肾病和吸入糖皮质激素亦与OR升高相关(1.06-1.64)。

要点

  • 算法在≥40岁使用带状疱疹剂量抗病毒药者中确认带状疱疹的比例为87%(95%CI 79-93%)。
  • 带状疱疹发病率从40岁的2.15/1000人年升至95岁的9.45/1000人年,女性最高。
  • 严重免疫抑制者带状疱疹OR最高(1.82-4.12),多种慢性病OR为1.06-1.64。

核心结论

  • 该算法是基于常规医疗数据识别带状疱疹的有效工具,显示带状疱疹在丹麦常见,尤其在某些慢性病患者中。
  • 在考虑替代普遍接种的国家,优先为这类高危患者接种疫苗可能是一种选择。

研究设计与样本

  • 基于丹麦全国健康登记数据的算法开发与验证研究,含验证子研究(n=176)、队列研究(45,297,258人年)和病例对照研究(189,025例带状疱疹病例 vs 945,111名匹配人群对照)。
  • 纳入1997-2013年≥40岁首次使用全身阿昔洛韦、伐昔洛韦或泛昔洛韦处方或住院带状疱疹诊断的患者。

主要发现

  • 验证子研究中,≥40岁使用带状疱疹推荐剂量抗病毒药者经病历复核确认带状疱疹的比例为87%(95%CI 79-93%)。
  • 带状疱疹发病率从40岁的2.15/1000人年升至95岁的9.45/1000人年,女性发病率最高。
  • 3.5%的带状疱疹在住院期间诊断。
  • 严重免疫抑制者的带状疱疹OR最高(1.82-4.12),多种自身免疫病、哮喘、慢性肾病和吸入糖皮质激素亦与OR升高相关(1.06-1.64)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes zoster (HZ) is a vaccine-preventable disease caused by reactivation of the varicella-zoster virus. Unfortunately, formulation of recommendations on routine immunization is hampered by a lack of data on disease burden, since most countries do not record cases of HZ in the general population. We developed and validated an algorithm to identify HZ based on routinely collected registry data and used it to quantify HZ occurrence and risk factors in Denmark prior to marketing of the HZ vaccine. METHODS: We included patients aged ≥40years with a first-time systemic Acyclovir, Valacyclovir, or Famciclovir prescription or a hospital-based HZ diagnosis in the Danish nationwide health registries during 1997-2013. In a validation substudy (n=176), we computed the proportion of persons with HZ among patients who redeemed antiviral prescriptions. In a cohort study, we computed age-specific rates of HZ (45,297,258 person-years). In a case-control study, we then computed odds ratios (ORs) for common chronic diseases and immunosuppressive factors among HZ cases (n=189,025) vs. matched population controls (n=945,111). RESULTS: Medical record review confirmed HZ in 87% (95% confidence interval: 79-93%) of persons ≥40years who dispensed antivirals at doses recommended for HZ. HZ rates increased from 2.15/1000 person-years in 40-year-olds to 9.45/1000 person-years in 95-year-olds. Rates were highest in women. HZ was diagnosed during hospitalization among 3.5%. As expected, persons with severe immunosuppressive conditions had the highest ORs of HZ (between 1.82 and 4.12), but various autoimmune diseases, asthma, chronic kidney disease, and inhaled glucocorticoids were also associated with increased ORs (between 1.06 and 1.64). CONCLUSION: This algorithm is a valid tool for identifying HZ in routine healthcare data. It shows that HZ is common in Denmark, especially in patients with certain chronic conditions. Prioritized vaccination of such high-risk patients might be an option in countries considering alternatives to universal vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Schmidt SAJ, Vestergaard M, Baggesen LM, et al. Prevaccination epidemiology of herpes zoster in Denmark: Quantification of occurrence and risk factors. Vaccine. 2017. PMID: 28874322. doi:10.1016/j.vaccine.2017.08.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。